Entera Bio Names Geno Germano Independent Board Chairman

An announcement from Entera Bio ( (ENTX) ) is now available.

Entera Bio announced on February 9, 2026, that its board appointed veteran pharmaceutical executive Geno J. Germano as chairman, effective February 4, 2026, succeeding Gerald Lieberman, who resigned the same day without any disagreement over company matters. The board has deemed Germano an independent director, and he will participate in Entera’s standard non-employee director compensation program.

Germano, a former Group President of Pfizer’s Global Innovative Pharma Business and ex-CEO of Elucida Oncology, brings more than three decades of development and commercialization experience, including leadership of a $14 billion innovative medicines portfolio and multiple board roles at biotech firms. His appointment comes as Entera prepares two oral PTH peptide programs for clinical milestones in 2026, including a Phase 3 registrational trial for EB613 in osteoporosis and a first-in-human study for a long-acting oral PTH in hypoparathyroidism, underscoring the company’s transition into late-stage development and its ambition to reshape treatment paradigms in bone and metabolic diseases.

The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.

Spark’s Take on ENTX Stock

According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.

The score is held back primarily by weak financial performance (minimal/declining revenue, persistent losses, and cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting support comes from low leverage/improved equity and positive corporate developments (expanded OPKO collaboration and FDA Phase 3 agreement), while valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on ENTX stock, click here.

More about Entera Bio

Entera Bio Ltd., based in Tel Aviv and listed on Nasdaq as ENTX, is a clinical-stage biotechnology company developing oral peptide and protein replacement therapies for significant unmet medical needs. Leveraging its proprietary N-Tab platform, Entera’s pipeline includes first-in-class oral candidates targeting PTH(1-34), GLP-1 and GLP-2 for osteoporosis, hypoparathyroidism, obesity, metabolic syndromes and rare malabsorption disorders.

Its lead asset, EB613, is an oral, once-daily osteoanabolic PTH(1-34) tablet for post-menopausal women with low bone mineral density and high-risk osteoporosis, which has already met primary and secondary endpoints in a Phase 2 study. The company is also advancing EB612 for hypoparathyroidism, an oral oxyntomodulin program for obesity and metabolic disease, and an oral GLP-2 candidate for short bowel syndrome and related conditions in collaboration with OPKO Health.

Average Trading Volume: 174,469

Technical Sentiment Signal: Sell

Current Market Cap: $47.69M

See more insights into ENTX stock on TipRanks’ Stock Analysis page.